Since knocking down GSK3α in prostate cancer cells is much more effective in inhibiting prostate tumor growth and colonization compared to GSK3β, our study reveal that inhibition of GSK3α or even better, pharmacological inhibition of both GSK3 isoforms will be an effective strategy for prostate cancer therapy. This evidence concerns the gene GSK3B and prostate neoplasm.